Founders at small and mid-size biotech oncology teams
Need a clear MOA piece for the deck. 15 to 25 day delivery, fixed price.

Oncology pipelines move fast and need visual storytelling that keeps up. From kinase inhibitors to ADCs to bispecific T-cell engagers and CAR-T platforms, CDI Studio builds animations that explain mechanism, biomarker rationale, and clinical positioning. Built for small and mid-size biotech, pharma, and drug-related teams.
Explore mechanism of action animation and medical animation pricing.
CDI internal benchmark
2D from $5K, 3D from $15K, custom above
CDI internal benchmark
Need a clear MOA piece for the deck. 15 to 25 day delivery, fixed price.
Field team training assets and slide-deck inserts that match label language.
Investor and HCP videos with consistent visual identity across markets.
Single mechanism, one to two pathway depth, end card with brand and indication. Standard 30 to 60 second length.
Vertical 9:16 cut for LinkedIn and conference walkup screens.
Multi-mechanism platform overview, scoped at discovery as a 3D Custom piece.
Liver cancer recurrence is a major challenge in oncology, often leading to tumor progression and requiring continuous monitoring and treatment. This high-quality 3D medical animation provides a visually engaging and scientifically accurate representation of how liver cancer can reoccur, the factors influencing tumor regrowth, and the biological mechanisms behind cancer progression. Key Highlights: How liver cancer recurs after treatment Tumor progression mechanisms and risk factors 3D visualization of liver cells & cancerous growth Medical animation for oncology research, education, and awareness This video is designed for medical professionals, researchers, students, and healthcare educators to better understand liver cancer recurrence and its impact on treatment strategies. If you found this animation insightful, don’t forget to like, share, and subscribe for more cutting-edge 3D biomedical animations!
Cancer is an uncontrolled growth of abnormal cells anywhere in a body. Since its diagnosis is expensive, people often discontinue their therapeutic procedures. For this purpose, Forti-Health introduced a feasible screening test to detect malignant cells. The test will only require a blood sample that simply detect the levels of fortilin - a potential biomarker found in the circulation which is expressed higher in cancerous cells as compared to normal ones. By preceding such a viable diagnostic test, patients who are undergoing cancer treatments can now conveniently monitor their health condition with much safer approaches.
Yes. We sign mutual NDAs and treat target identity, structure, and mechanism as confidential. Storyboards and renders never leave a controlled review folder.
We work alongside your scientific team at every stage. Structures are reviewed against PDB references and peer-reviewed mechanism papers, with documented references at storyboard sign-off.
Often. We can plug into your agency's existing stylebook, lock to your client's medical legal review cycle, and white-label the production credit.
Send us your science, target audience, and deadline. We will scope and price within 48 hours.